Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

The financial performance indicators demonstrate fluctuations over the five-year period. Net income, Earnings Before Tax (EBT), Earnings Before Interest and Tax (EBIT), and Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) all exhibit distinct patterns of change between 2021 and 2025.

Overall Trend

EBITDA experienced a decline from 2021 to 2023, followed by a recovery and subsequent growth in 2024 and 2025. The highest EBITDA value was recorded in 2021 at US$9,669,300, while the lowest was in 2023 at US$4,693,300. By 2025, EBITDA had risen to US$5,818,200, though it did not surpass the 2021 peak.

EBITDA vs. Other Earnings Measures

EBITDA consistently exceeded EBT and Net Income throughout the observed period. The difference between EBITDA and EBIT was relatively stable, reflecting consistent depreciation and amortization expenses. The gap between EBIT and EBT was minimal, indicating limited interest expense. The largest decrease in all earnings measures occurred between 2021 and 2022, suggesting a significant shift in financial performance during that period.

Year-over-Year Changes

A substantial decrease in EBITDA was observed from 2021 (US$9,669,300) to 2022 (US$5,259,600), representing a decline of approximately 45.6%. From 2022 to 2023, EBITDA continued to decrease, albeit at a slower rate, falling to US$4,693,300. A turnaround began in 2024, with EBITDA increasing to US$5,318,000, and this positive trend continued into 2025, reaching US$5,818,200. The growth rate from 2024 to 2025 was approximately 9.4%.

The observed fluctuations in EBITDA suggest potential impacts from changes in revenue, operating costs, or both. The recovery in 2024 and 2025 indicates a potential stabilization or improvement in underlying business conditions. Further investigation into the drivers of these changes would be necessary for a more comprehensive understanding.

The Enterprise Value to EBITDA ratio exhibits significant fluctuation over the observed period. Initially, the ratio increased substantially before stabilizing in the later years. A detailed examination of the components and the resulting ratio reveals key trends.

Enterprise Value (EV)

Enterprise Value increased from US$64.56 million in 2021 to US$80.33 million in 2022, representing a substantial rise. It continued to increase, reaching US$94.63 million in 2023, before declining to US$72.05 million in 2024. A modest increase to US$76.04 million is observed in 2025. This suggests periods of expansion followed by contraction in the company’s total value.

Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA)

EBITDA experienced a considerable decrease from US$9.67 million in 2021 to US$5.26 million in 2022. This downward trend continued into 2023, with EBITDA falling to US$4.69 million. A slight recovery occurred in 2024, with EBITDA reaching US$5.32 million, and further improvement was seen in 2025, rising to US$5.82 million. The pattern indicates initial profitability decline followed by a stabilization and modest recovery.

EV/EBITDA Ratio

The EV/EBITDA ratio began at 6.68 in 2021. It rose sharply to 15.27 in 2022, driven by the increase in Enterprise Value and the decrease in EBITDA. The ratio peaked at 20.16 in 2023, reflecting continued pressure from declining EBITDA. In 2024, the ratio decreased to 13.55, influenced by the decline in Enterprise Value. The ratio stabilized at 13.07 in 2025, indicating a potential leveling off of valuation relative to earnings.

The significant increase in the EV/EBITDA ratio between 2021 and 2023 suggests that the market valuation grew at a faster rate than the company’s operational earnings. The subsequent decrease in 2024 and stabilization in 2025 may indicate a correction in valuation or a response to the modest recovery in EBITDA. The interplay between Enterprise Value and EBITDA is the primary driver of the observed ratio fluctuations.